Celgene Pays $340 Million For Gloucester And Its New Drug
Celgene already sells several hematological cancer meds, so the deal shouldn't require new marketing infrastructure.
Celgene already sells several hematological cancer meds, so the deal shouldn't require new marketing infrastructure.